Spyre Therapeutics
SYRE
SYRE
94 hedge funds and large institutions have $275M invested in Spyre Therapeutics in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
94
Holders Change
+7
Holders Change %
+8.05%
% of All Funds
1.9%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
17
Increased
23
Reduced
31
Closed
10
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K
Top Buyers
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.05M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$2.91M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.66M |
| 4 |
Axa
Paris,
France
|
+$2.16M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.71M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$7.63M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.42M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.5M |
| 4 |
Renaissance Technologies
New York
|
-$1.47M |
| 5 |
BlackRock
New York
|
-$631K |